Adaptive Biotechnologies (ADPT) Announces Preliminary Revenue Results, CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition
January 10, 2022 8:30 AM ESTSEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for the year ended December 31, 2021 is estimated to be in the range of $153 million to $154 million, representing an approximate increase of 56% at the mid-point of the range compared to $98.4 million for the year ended December 31, 2020.
The Adaptive team delivered strong results in 2021, setting the stage to accelerate our immune medicine and MRD business areas, said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. Our goal is to... More
